E-LIB Suche - Ergebnisse für: Guillo, Lucas

1

Higher Adalimumab Concentration is Associated with Complete..:

Papamichael, Konstantinos ; Centritto, Andrea ; Guillo, Lucas...
Clinical Gastroenterology and Hepatology. , 2024

Link: https://doi.org/10.1016/..

2

Su1803 HIGHER MAINTENANCE ADALIMUMAB CONCENTRATION IS ASSOC..:

Papamichail, Konstantinos ; Centritto, Andrea ; Guillo, Lucas...
Gastroenterology. 166 (2024) 5 - p. S-821 , 2024

Link: https://doi.org/10.1016/..

3

1176 EFFECTIVENESS AND SAFETY OF SUBCUTANEOUS INFLIXIMAB IN..:

André, Marie ; Kirchgesner, Julien ; Laharie, David...
Gastroenterology. 166 (2024) 5 - p. S-280-S-281 , 2024

Link: https://doi.org/10.1016/..

4

Patient preferences for adalimumab in inflammatory bowel di..:

Caron, Bénédicte ; Seksik, Philippe ; Buisson, Anthony...
Therapeutic Advances in Gastroenterology. 17 (2024) - p. , 2024

Link: https://doi.org/10.1177/..

5

Tofacitinib for Patients with Anti-TNF Refractory Ulcerativ..:

Uzzan, Mathieu ; Nachury, Maria ; Nuzzo, Alexandre...
Journal of Crohn's and Colitis. 18 (2023) 3 - p. 424-430 , 2023

Link: https://doi.org/10.1093/..

6

Tu1755 HIGHER MAINTENANCE INFLIXIMAB CONCENTRATION IS ASSOC..:

Papamichail, Konstantinos ; Guillo, Lucas ; Hier, Jessica...
Gastroenterology. 164 (2023) 6 - p. S-1111 , 2023

Link: https://doi.org/10.1016/..

7

Prevalence of and factors associated with extraintestinal m..:

Guillo, Lucas ; Savoye, Guillaume ; Amiot, Aurélien...
Clinical and Translational Gastroenterology. , 2023

Link: https://doi.org/10.14309..

8

Efficacy and safety of combination targeted therapies in im..:

Guillo, Lucas ; Flachaire, Benoit ; Avouac, Jérôme...
Digestive and Liver Disease. 55 (2023) 1 - p. 61-68 , 2023

Link: https://doi.org/10.1016/..

9

Three-year outcome of local injection of autologous stromal..:

Guillo, Lucas ; Grimaud, Fanny ; Houser, Fanny...
Stem Cell Research & Therapy. 13 (2022) 1 - p. , 2022

Link: https://doi.org/10.1186/..

10

Prevalence of anti-TNF contraindications in Crohn's disease..:

Amiot, Aurelien ; Seksik, Philippe ; Reimund, Jean-Marie...
Digestive and Liver Disease. 54 (2022) 10 - p. 1350-1357 , 2022

Link: https://doi.org/10.1016/..

11

Management of immune checkpoint inhibitor in patients with ..:

Amiot, Aurelien ; Laharie, David ; Malamut, Georgia...
Digestive and Liver Disease. 54 (2022) 9 - p. 1162-1167 , 2022

Link: https://doi.org/10.1016/..

12

Endpoints for extraintestinal manifestations in inflammator..:

Guillo, Lucas ; Abreu, Maria ; Panaccione, Remo...
The Lancet Gastroenterology & Hepatology. 7 (2022) 3 - p. 254-261 , 2022

Link: https://doi.org/10.1016/..

13

Editorial: shedding new light on extraintestinal manifestat..:

Guillo, Lucas ; Peyrin‐Biroulet, Laurent ; Danese, Silvio
Alimentary Pharmacology & Therapeutics. 55 (2022) 9 - p. 1206-1207 , 2022

Link: https://doi.org/10.1111/..

14

Prevalence of Self-Reported Venous Thromboembolism and Card..:

Guillo, Lucas ; Amiot, Aurélien ; Serrero, Mélanie...
Digestive Diseases and Sciences. 67 (2022) 9 - p. 4525-4532 , 2022

Link: https://doi.org/10.1007/..

15

Kidney function monitoring in inflammatory bowel disease: T..:

Guillo, Lucas ; Delanaye, Pierre ; Flamant, Martin...
Digestive and Liver Disease. 54 (2022) 3 - p. 309-315 , 2022

Link: https://doi.org/10.1016/..